Expression of feline immunodeficiency virus Vif is associated with reduced viral mutation rates without restoration of replication of vif mutant viruses  by Paul, Thomas A. et al.
7) 112–122
www.elsevier.com/locate/yviroVirology 361 (200Expression of feline immunodeficiency virus Vif is associated with reduced
viral mutation rates without restoration of replication of vif mutant viruses
Thomas A. Paul a, James W. Casey a,⁎, Roger J. Avery b, Claudia A. Sutton a
a Department of Microbiology and Immunology, Cornell University, C4-137 Veterinary Medical Center, Ithaca, NY 14853, USA
b Virginia Polytechnic Institute and State University, Department of Biomedical Sciences and Pathobiology, Blacksburg, VA 24061, USA
Received 14 August 2006; returned to author for revision 8 September 2006; accepted 8 November 2006
Available online 12 December 2006Abstract
The vif gene of lentiviruses has been demonstrated to be essential for efficient viral replication in many cell types. Although the Vif protein of
feline immunodeficiency virus (FIV) displays limited homology to HIV-1 Vif, the role of vif in FIV replication is not known. We have examined
the requirements of vif for replication of a FIV strain isolated from a non-domestic felid, Otocolobus manul (FIV-Oma). In agreement with others,
we find that replication of FIV vif mutant molecular clones in CrFK cells is highly attenuated. Initial attempts to rescue vif mutant viruses in trans
were limited by lack of detectable wild-type Vif expression from DNA constructs. We demonstrate that FIV-Oma Vif expression can be increased
by re-synthesis of the gene to remove splice donor and acceptor sites as well as improving codon usage to a mammalian codon optimized model.
Cellular localization of resynthesized Vif (Vif-RS) is cytoplasmic. Clonal stable transfectants expressing HA-tagged Vif-RS do not restore
replication levels of vif mutant virus. However, in such cell lines, G-to-A mutation rates in replicating wild-type viruses are reduced.
© 2006 Elsevier Inc. All rights reserved.Keywords: FIV; Vif; Lentivirus; APOBEC3G; FIV-Oma; Virus mutation; RetrovirusIntroduction
The viral infectivity factor (vif) is an accessory gene
identified in all lentiviruses with the exception of equine
infectious anemia virus (EIAV) (Kawakami et al., 1987; Oberste
and Gonda, 1992). Although sequence similarities among Vif
proteins are limited between lentiviruses (Oberste and Gonda,
1992), deletion or mutation of vif in human immunodeficiency
virus type 1 (HIV-1) (Fisher et al., 1987; Gabuzda et al., 1992,
1994; Gibbs et al., 1994a; Strebel et al., 1987) and type-2 (HIV-
2) (Michaels et al., 1993; Shibata et al., 1990), simian
immunodeficiency virus (SIV) (Gibbs et al., 1994b; Shibata et
al., 1990), caprine arthritis encephalitis virus (CAEV) (Har-
mache et al., 1996), maedi-visna virus (MVV) (Kristbjornsdot-
tir et al., 2004) and feline immunodeficiency virus (FIV)
(Lockridge et al., 1999; Tomonaga et al., 1992) cause
significant defects in viral replication in many primary⁎ Corresponding author. Fax: +1 607 253 3384.
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0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
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cells. However, in a subset of cell lines termed “permissive,”
HIV-1 vif appears dispensable for viral replication (Courcoul et
al., 1995; Fan and Peden, 1992; Fisher et al., 1987; Maki et al.,
1992). The conflicting requirement of vif in viral replication has
been resolved from studies differentiating cellular factors
involved in HIV-1 viral replication in permissive and non-
permissive cell types (Madani and Kabat, 1998; Simon et al.,
1998; Sheey et al., 2002). A cellular protein, APOBEC3G,
expressed exclusively in non-permissive cells, has been
identified as the negative regulator of HIV-1 and SIV-1 vif-
defective viral replication (Madani and Kabat, 1998; Sheey et
al., 2002; Simon et al., 1998; Stopak et al., 2003; Yu et al.,
2004a, 2004b). APOBEC3G, a member of the apolipoprotein B
mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)
family of cytidine deaminases, is specifically packaged into
HIV-1 virions and then blocks productive infection by
catalyzing the deamination of deoxycytidine to deoxyuridine
on the DNA minus strand during reverse transcription (Harris et
al., 2003; Jarmuz et al., 2002; Lecossier et al., 2003; Mangeat et
113T.A. Paul et al. / Virology 361 (2007) 112–122al., 2003; Zhang et al., 2003). HIV-1 Vif abrogates the
attenuation of HIV-1 vif mutant replication in non-permissive
cells by recruiting an E3-ubiquitin ligase to APOBEC3G,
thereby leading to its polyubiquitination, proteasomal degrada-
tion, and exclusion from assembling virus particles (Conticello
et al., 2003; Marin et al., 2003; Sheehy et al., 2003; Yu et al.,
2003). In addition, HIV-1 Vif inhibits the translation of
APOBEC3G mRNA, further reducing levels of the enzyme
within the cell (Stopak et al., 2003). Other members of the
human APOBEC family, APOBEC3B and APOBEC3F, have
also been associated with the inhibition of HIV-1 and HIV-2
replication (Bishop et al., 2004; Liddament et al., 2004;
Wiegand et al., 2004; Zheng et al., 2004).
The vif gene of feline immunodeficiency virus (FIV) is
similar in size and genome location to the vif gene of primate
lentiviruses (Tomonaga et al., 1992). It encodes a protein that is
highly hydrophilic and basic from spliced viral transcripts
containing rev-responsive elements. Similar to primate lenti-
viruses, the C-terminus of FIV Vif contains a consensus (SLQY
(L/R)A) BC box motif. In HIV-1 Vif, this motif and an
additional upstream zinc-finger motif has been demonstrated to
complex with Cullin5, Elongin B, Elongin C, and Rbx1 to form
a ubiquitin ligase (E3) complex which targets APOBEC3G and
APOBEC3F for degradation (Mehle et al., 2006; Shirakawa et
al., 2006; Yu et al., 2004a, 2004b). The conservation of the BC
box motif in FIV Vif suggests that APOBEC3G inhibition may
be a conserved function of lentivirus Vif proteins. In support of
this, mutation of FIV Vif, including point mutations in the BC
box, results in impaired cell-free infection of feline peripheral
blood mononuclear cells (PBMCs) and established feline cell
lines such as G355-5, CrFK, and MYA-1 (Lockridge et al.,
1999; Shacklett and Luciw, 1994; Tomonaga et al., 1992).
Additionally, FIV vif has been shown to be necessary for
efficient viral replication during in vivo infections of cats
(Inoshima et al., 1996). Although a cell line permissive for
replication of vif-defective FIV strains has yet to be identified,
Tomonaga et al. (1992) have shown that virus produced from
CrFK cells transfected with a vif mutant molecular clone of FIV
could infect a CD4+T-cell line (Mya 1) by co-cultivation of
T-cells with virus producing CrFK cells. Thus, in this system,
Vif expression appears necessary to achieve cell-free infectivity,
but dispensable for virus spread via cell-to-cell contact.
To further elucidate the role of vif in the FIV lifecycle, we
have attempted to rescue infection of FIV vif mutant virus by
expression of Vif in trans. A molecular clone of FIV-Oma,
derived from a highly cytopathic FIV strain from a Pallas cat
(Barr et al., 1995, 1997) was utilized in this study due to this
isolates replication efficiency and syncytium formation in
CrFK cells compared to domestic FIV isolates (Barr et al.,
1995). In this study, we have found that mutant FIV-Oma
infectious clones with frameshift and deletion mutations in
vif, replicate at lower levels compared to wild-type virus in
CrFK cells. Replication of vif mutant FIV could not be
restored by expression of wild-type Vif in trans. However,
levels of G-to-A mutations in proviral DNA are reduced by
infection of wild-type virus in a Vif-expressing cell line.
Thus, FIV Vif may function similarly to HIV-1 Vif inpreventing APOBEC-induced mutagenesis of proviral DNA
during reverse transcription.
Results
vif mutant virus replication is attenuated
Using the infectious clone of the FIV Oma strain, pOma3, as
starting material, we generated two different vif mutant viruses
(Fig. 1A). The first, termed FIV VifΔ, was constructed by
deleting the sequence between two unique StuI sites within the
vif open reading frame. This deletion mutant removes 302 bp
within the vif open reading frame (positions 325–626), however
maintains predicted splice donor and acceptor sites within the
resultant vif transcript. Additionally, a frameshift as a result of
the deletion of the wild-type Vif protein adds eight missense
codons after amino acid 109 and prematurely terminates
translation. A second vif mutant, FIV Vif-fs, was created by
insertion of a TA dinucleotide between base pairs 66 and 67 that
forms a translation stop codon after amino acid 22. Since this
mutant retains the complete vif sequence, it is unlikely that
processing of the downstream subgenomic transcripts is altered
in this mutant.
To assess the replication efficiency of vif mutant viruses, we
transfected CrFK cells with molecular clones for wild-type
virus (pOma3) and the two vif mutant viruses (FIV VifΔ and
FIV Vif-fs). Monitoring of cell culture supernatant for reverse
transcriptase (RT) activity, an indication of viral particle release,
shows a peak in RT activity at day 11 for cells transfected with
the wild-type virus that subsided at day 14, at which point cells
displayed cytopathic effects (CPE) associated with viral
replication (Fig. 1B). Supernatant from cells transfected with
FIV Vif-fs displayed detectable RT activity at levels approxi-
mately eightfold lower than the wild-type virus at day 11. These
data suggest that low levels of viral particles are released from
cells transfected with the FIV Vif-fs mutant clone; however,
formation of viral particles or their release is impaired due to the
vif mutation. RT activity above background could not be
detected in supernatant of cells transfected with the FIV
VifΔ virus (Fig. 1B), indicating that viral replication is
completely restricted in this clone. CPE were not observed in
CrFK cells transfected with either vif-mutant molecular clone
(data not shown).
Expression of tagged Oma3 Vif is not detectable in mammalian
cells
To evaluate the role of vif in the FIV viral life cycle, we
sought to generate lines of CrFK cells that express Vif. During
the course of these experiments, achieving detectable levels of
Vif protein expression proved problematic. In addition, FIV-
Oma Vif was poorly antigenic in rabbits (data not shown) and,
therefore, had to be fused to an epitope tag in order to visualize
cellular localization and expression. In a first set of experiments,
we cloned vif as a C-terminal fusion to enhanced green
fluorescent protein (EGFP), referred to as EGFP-Vif, to monitor
in vivo expression levels. In these experiments, transfection of
Fig. 1. (A) Wild-type and mutant forms of FIV Vif used in this study. Wild-type vif gene comprises 759 bp between positions 5429 and 6187 bp of the pOma3 FIV
molecular clone. Translation of the full-length vif transcript is predicted to expresses a protein 252 a.a. in length denoted by the shaded area. The wild-type vif transcript
contains predicted splice donor and acceptor sites after positions 24 and 689 bp within the vif open reading frame with the potential to produce a truncated 11 a.a.
protein product. The VifΔ virus is deleted between two StuI sites at 325 and 626 bp within vif open reading frame. The resultant transcript maintains sequences at the
3′ of the vif transcript (denoted by line) including the predicted splice acceptor site. The mutated open reading frame is predicted to express a 117 a.a. protein
containing 109 a.a. from the N-terminus of wild-type Vif and 8 a.a. from an alternative reading frame. The Vif-fs virus incorporates an extra base pair at position 67 of
the vif open reading frame causing a frame shift (fs) that terminates translation before amino acid 22. (B) Replication kinetics of FIV-Oma wild-type and mutant strains
FIV VifΔ and FIV Vif-fs in CrFK cells. Replication of virus was measured by reverse transcriptase activity in aliquots of 10 μL of media up to 14 days post-
transfection. Data presented represent the average RT activity for three independent transfected wells at each time-point.
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produced detectable levels of fluorescence at 24 h post-
transfection. However, when the expressed protein product
was evaluated by western blot using an antibody against EGFP,
the EGFP-Vif fusion protein exhibited a similar molecular
weight as control EGFP (Fig. 2A; compare lanes 2 and 3). To
test the ability of the EGFP-Vif construct to be properly
translated, we expressed the EGFP-Vif fusion in bacteria. After
a 2-h induction, western blots showed the EGFP-Vif fusion
protein at approximately 70 kDa (Fig. 2A, lane 4). Thus,
although the EGFP-Vif fusion protein was properly cloned and
capable of being translated in bacteria, it appears to be poorly
expressed in eukaryotic cells.
One possible explanation for the poor expression and
truncation of Vif fusion constructs is the improper splicing of
transcripts containing the vif open reading frame. The vif
transcript sequence contains a predicted splice donor site
between 24 and 25 nt (CAG/GUAAGU) and splice acceptor site
between 689 and 690 nt (CUUACAG/AUCACCU) (Fig. 1A).
Splicing of sequence within the vif open reading frame is
predicted to cause a frame shift resulting in the production of an
11 a.a. protein. To determine if use of these splice sites
contributes to the truncation of Vif fusion proteins in eukaryoticcells, we performed RNase protection analysis of CrFK cells
transfected with vectors expressing EGFP-Vif or HA-Vif. In this
assay, truncated vif transcripts consistent with use of the
predicted splice sites were protected by the vif probe
(Supplementary Fig. 1). We next created a truncated form of
vif (Vif sd-) by removing the first 24 bp from the 5′ end of
wild-type vif. The resulting open reading frame destroys the
predicted splice donor site and produces an eight amino acid N-
terminal truncation of the Vif protein. The truncated form of vif
was fused in-frame to the C-terminus of EGFP, creating EGFP-
Vif sd-. In CrFK cells transfected with the EGFP-Vif sd-vector,
a poorly expressed protein product near to the predicted size of
58 kDa was detected by western blot (Fig. 2B, lane 2). The
previous vector, EGFP-Vif, produced a shorter protein closer to
the 28 kDa predicted size of control EGFP (Fig. 2B, lane 3).
These observations suggest that the difficulty in translating full-
length Vif fusion proteins is due in part to splicing of the vif
portion of transcripts.
Resynthesis of codon-optimized vif
Examination of the vif sequence from positions 5429 to
6187 bp of pOma3 shows that codon usage is most similar to
Fig. 2. (A) Western blot for expression of EGFP (lane 2) and EGFP-Vif fusion
protein (lane 3) in CrFK cells. A molecular weight marker (lane 1) indicates that
both EGFP and EGFP-Vif are expressed at a molecular weight near 30 kDa.
Bacterial expression of EGFP-Vif (lane 4) is near the predicted size of the full-
length fusion protein of 58 kDa. (B) Western blot analysis of resynthesized Vif
fusion protein expression in CrFK cells. A codon optimized form of vif (EGFP-
Vif-RS) enabled detection of higher levels of full-length fusion protein near the
predicted size of 58 kDa (lane 2). Deletion of the first 33 bp of the vif open
reading frame including a predicted splice donor site in the vector EGFP-Vif sd-
enabled detection of a full-length fusion protein (lane 3). A C-terminal fusion of
wild-type vif to EGFP produced a shorter protein near the size of EGFP (lane 4).
Control CrFK cell lysate (lane 1) indicates the specificity of the anti-EGFP
antibody.
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codon position adenines (As) as opposed to guanines (Gs).
Synonymous codon changes that better reflect mammalian
codon usage and at the same time eliminated the splice
donor and acceptor consensus sequences were made to
improve Vif expression. The 252 codon vif was resynthe-
sized with 42 synonymous codon changes using 21
overlapping oligonucleotides (Table 1). The reassembled vif
gene was named vif-RS, and the sequence of this synthetic
gene is shown in Fig. 3.Table 1
Primers used for human codon optimization of the FIV-Oma vif open reading frame
Primer positions vif gene resynth
VIF 1F (55nt) GGATCCATGA
VIF 2 (55nt) ACTTCCGATA
VIF 3 (55nt) GGTCTTTTTT
VIF4 (55nt) TAGATAAATC
VIF5 (55nt) GAAAATAGAT
VIF5F (55nt) GAAAAGACC
VIF6 (56nt) CCACCAACTC
VIF7 (55nt) GAAAGAGTTG
VIF8 (55nt) AGTAGGCCGA
VIF9 (55nt) GTATCGGCCT
VIF10 (55nt) TTTGCTGGTT
VIF11 (55nt) CGAGAACCA
VIF11F (55nt) TCCGATATCC
VIF 12 (56nt) TTTTCTGGGC
VIF13 (56nt) CCTGCCCAGA
VIF14 (55nt) ACAGATCAGA
VIF15 (55nt) GGAATCTGAT
VIF16 (55nt) ACATCCCACC
VIF17 (55nt) TTGGGTGGGA
VIF18 (55nt) TACAACACTT
VIF19 (37nt) CTATGAAGTGCellular localization of Vif
vif-RS was cloned as a C-terminal fusion to EGFP and the
resultant expression construct was transfected into CrFK cells.
A protein consistent with the predicted molecular weight of
the EGFP-Vif-RS fusion protein was detected by western blot
(Fig. 2B, lane 2). To control for possible artifacts in Vif
localization due to fusion to EGFP, a second Vif-RS fusion
was made that replaces the EGFP reporter with an N-terminal
3X-HA epitope. Western blots of both stably and transiently
transfected cells showed a reactive species near the predicted
35 kDa molecular weight of the HA-Vif-RS fusion (data not
shown). The cellular localization of the HA-Vif-RS fusion was
tested in CrFK cells stably transfected with the HA-Vif-RS
expression vector. Immunofluorescence using an antibody for
the HA epitope tag detected expression of HA-Vif-RS
dispersed evenly throughout the cytoplasm; however, expres-
sion was excluded from the nucleus (Figs. 4C, D). CrFK cells
stably transfected with HA-Vif-RS and infected with Vif-Oma
virus demonstrate cytoplasmic localization of both HA-Vif-RS
(right panel) and FIV p24 Gag (left panel) (Figs. 4E, F).
Similar cytoplasmic staining for HA-Vif-RS has been
observed in transiently transfected MDCK cells as well as in
CrFK cells using fixation with either paraformaldehyde or
methanol (data not shown).
HA-Vif-RS expression in trans does not rescue vif mutant FIV
replication
The ability of Vif expression in trans to rescue attenuation
of vif mutant FIV strains was tested in CrFK cells stably
transfected with HA-Vif-RS. Two separate HA-Vif-RS-expres-
sing clones were transfected with molecular clones for wild-
type FIV-Oma, or vif mutant FIV VifΔ or FIV Vif-fs toesis primer sequences
GTGGTGAAGAGGATTGGCAAGTCTCCCGCTCTCTCTATCAAGTGC
TAGAGCATAGCTCTTCTAGGTCCCCCCAGAAGCACTTGATAGAGA
CTTTCTAGCCTTTTCCTTTTCATCGATGATACTTCCGATATAGAG
TATTTTCCAGTCTAGCCATTCTTTTTTGCAGGTCTTTTTTCTTTC
TTATCTATTGGCCTAGGAGACAAGAAGGGATCAGATGGTCTTTTC
ATCTGATCCCTTCTTGTCTCCTAGGCCAATAGATAAATCTATTC
TTTCACAAATCCCAGATGATAATCTCTTGTATGAAAAGACCATCTG
GTGGCAGGAAGCTCTAGTCCTGGATGTTTGAGATTGTATTGTTAC
TACCTTTTATGCCACAATGGATTACTAATGTAACAATACAATCTC
ACTTTGCAGATGAATCAAGAATTTCCATATGTGAATTGTTGGATT
CTCGATATCATCCCACATAAATTTATCGGTAATCCAACAATTCAC
GCAAATTATGAAGAGTCCTTTGCCTGGTCCAGGATGGGATATCGGA
CATCCTGGACCAGGCAAAGGACTCTTCATAATTTGCTGGTTG
AGGAATATGCTTTGATCACCAATCCCACCATTCCGATATCCCATC
AAAGAAGTATGATGTGACAATCCCACAGGTGATCCGGGGAGAAAAA
TTCCAACAATCAGCACAAAATTCTTGAGGATCTTTTTCTCCCCGG
CTGTGTGAGGAATTCCCCACCATGTAGTCTGCAAAGATTGGCTTT
CAACTTTCTGTTGGTTTGCCACAGGCCTTCAAAGCCAATCTTTGC
TGTTGCAACCACAGATTTTTGTCTCCTTACAGATCTCCTACTGAC
CATAGGGCACAGCTTCTCTGACGATCAACAAGTCAGTAGGAGATC
TTGTATCGGATGAAGAGTACTCTCGAG
Fig. 3. Codon optimized sequence of FIV-Oma vif-RS with predicted translation is shown in bold. Numbers on the right indicate nucleotide positions within the
resynthesized open reading frame.
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activity for the ability of the Vif-expressing cells to rescue vif
mutant viruses. During a 14 day period, neither HA-Vif-RS-
expressing cell lines was capable of restoring infectivity of
either vif mutant virus (data not shown). Wild-type FIV-Oma
virus replicated with slower kinetics in the two HA-Vif-RS-
expressing cell lines compared to control CrFK cells; RT
activity was first detected at day 13 post-infection (p.i.) in
infected control CrFK cells versus day 18 p.i. and day 22 p.i.
in the two HA-Vif-RS-expressing clonal cell lines (Fig. 5).
Additionally, virus replicating in HA-Vif-RS-expressing cells
displayed higher RT activity and delayed CPE compared to
replication in control cells (Fig. 5). At the termination of the
experiments due to virus-induced cell death at day 18 p.i. in
control CrFK cells and at day 25 in HA-Vif-RS CrFK clones,
HA-Vif-RS-expressing cells displayed 2.3–3 times the RT
activity of control cells.
Vif expression in trans reduces mutation of pOma3 provirus in
infection
If the FIV Vif protein acts in a similar manner to HIV Vif
in blocking the packaging of cellular APOBEC3G, we
hypothesized that Vif expression in trans might reduce
deamination derived mutations in proviral DNA. We initiated
infection of control CrFK cells and the two HA-Vif-RS-
expressing clonal cell lines by infection with cell-free
supernatant from pOma3 transfected cells. Plus-strand virion
DNA was isolated from pelleted viral particles and the
frequency of viral mutations was detected by PCR amplifica-
tion of a 592 bp region in pol containing 118 Gs from each
culture at 7 and 10 days p.i. PCR-amplified fragments were
cloned and multiple clones were DNA sequenced. The
resultant sequences were analyzed for G-to-A base changes
indicative of cytidine deamination of the DNA minus strand.In control FIV infected CrFK cells, G-to-A conversions were
detected, averaging 2.18 and 2.61 sites per 118 Gs in the
amplicon at day 7 and day 10, respectively (Table 2). This
compares to an average mutation rate of 0.27 and 0.16
changes per site at day 7 and day 10 for all other positions in
the 592 bp pol region. The frequency of G-to-A exchanges in
individual clones ranged from 0 to 7 at day 7 and 0 to 6 at day
10. In contrast, G-to-A exchanges were reduced in viral DNA
to an average of 0.13 and 0 sites per 118 guanine positions in
two separate HA-Vif-RS-expressing cell lines at day 7 (Table
2). At day 10, a slight increase in G-to-A conversions was
detected, averaging 0.5 to 0.38 sites per 118 Gs in FIV-Oma
infected Vif-expressing cell lines. Individual clones contained
between 0 and 2 G-to-A exchanges per sequence at day 10.
Mutation rates of non-guanine positions in FIV pol ranged
from 0.28 to 0.38 changes at day 7 and 0.21 to 0.23 changes at
day 10 per 474 positions analyzed.
Discussion
In this study, we sought to better define the role of vif in the
FIV viral life-cycle in light of recent studies in primate
lentiviruses demonstrating a role for Vif in preventing
APOBEC3G-induced cytosine deamination during minus
strand synthesis. Similar to previous reports with different
FIV isolates (Lockridge et al., 1999; Shacklett and Luciw, 1994;
Tomonaga et al., 1992), replication of several vif mutant viruses
of a non-domestic cat isolate of FIV (FIV-Oma) displayed
highly attenuated replication in CrFK cells compared to wild-
type virus. As opposed to the primate lentiviruses (Blanc et al.,
1993; Simon et al., 1995), replication of vif mutant forms of
FIV-Oma could not be restored by infection of cell lines stably
expressing Vif in trans. However, wild-type viruses replicating
in Vif-expressing cell lines displayed fewer G-to-A mutations,
suggesting that FIV Vif may act in a manner similar to primate
Fig. 4. Immunofluorescence of CrFK cells stably transfected with HA-Vif-RS using an anti-HA antibody indicates HA-Vif-RS expression in cytoplasmic (C) and
excluded from the DAPI stained nucleus (D). Control CrFK similarly stained with anti-HA antibody indicates that expression is specific for the stably transfected cell
line (A, B). CrFK cells infected with FIV-Oma and stably transfected with the HA-Vif-RS expression construct (E, F). Antibody to FIV p24 detects FIV infection of a
syncytium (E) that also expresses HA-Vif-RS detected with an anti-HA antibody (F). Expression of both proteins appears confined to the cytoplasm.
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nascent viral DNAs.
We have observed differences in the replication kinetics of
two separate FIV-Oma vif mutant viruses. The first mutant,
containing a premature stop codon after amino acid 21 (FIV
Vif-fs) maintained low levels of detectable RT activity in the
supernatant of transfected cells that slightly increased over the
course of 2 weeks. It is possible that the FIV Vif-fs virus is
capable of maintaining low levels of virus production by
direct cell-to-cell transmission previously reported for other
FIV vif mutant viruses (Shacklett and Luciw, 1994; Tomonagaet al., 1992). However, FIV Vif-fs does not appear capable of
initiating cell-free infection as filtered supernatant from
transfected CrFK cells was unable to initiate de novo infection
in CrFK cells (data not shown). A second vif mutant, FIV
VifΔ, a 117 amino acid truncated form of FIV Vif, had
undetectable RT activity suggesting that both cell-to-cell and
cell-free transmission are completely restricted. As the FIV
VifΔ mutant possesses a deletion from positions 325 to
626 bp of vif, we cannot rule out that the phenotype of the
FIV VifΔ mutant is attributed to the disruption of viral
regulatory sequences within the mutation site affecting the
Fig. 5. Replication kinetics of FIV-Oma infection in control CrFK cells and two
clones of CrFK cells stably expressing Vif-RS. Replication of virus was
measured by reverse transcriptase activity in aliquots of 10 μL medium. Data
presented represent the average RT activity for three independent transfected
wells at each time-point. Experiments were terminated at day 18 for normal
CrFK cells and day 25 for CrFK cells expressing Vif-RS due to virus-induced
cell death.
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vif transcripts in both mutant viruses retain predicted splice
donor and acceptor sites (Fig. 1A). Thus, additional regulatory
sites within the deleted region might be disrupted as a result
of the 302 bp deletion in the FIV VifΔ mutant.
Our attempts to rescue the phenotype of the FIV-Oma
vif mutants were hindered by poor expression of Vif in
cell culture. High levels of HIV-1 Vif expression have also
been difficult to achieve due to inefficient nuclear export of
vif transcripts, poor mammalian codon usage, and high turnover
rate of Vif protein (Fujita et al., 2004; Nguyen et al., 2004;
Wang et al., 2005). Restricted vif-expression levels may
represent a selective advantage for retroviral replication. Akari
et al. (2004) suggested that high protein turnover rates of HIV-1
Vif prevent the improper processing of Gag polyproteins during
virus maturation. Cells over-expressing HIV-1 Vif accumulate
Gag processing intermediates and exhibit impaired replication
rates compared to cells expressing Vif at physiological levels
(Akari et al., 2004). Interestingly, we found that wild-type FIV-
Oma replication in FIV Vif-expressing cells displays delayed
replication kinetics and attains higher supernatant RT activity
before the onset of virus-induced cytopathic effects. This
suggests that high levels of FIV Vif expression in our system
may have negative consequences on the replication of wild-type
FIV.Table 2
Frequency of G-to-A base changes detected in FIV-Oma DNA genomes during infe
Cell Line Day 7
Mean G-to-A changes a
(range)
Mean other base
changes b
Se
C
CrFK control 2.18 (0-7) 0.27 11
CrFK Vif-RS Clone 1 0.13 (0-2) 0.28 15
CrFK Vif-RS Clone 2 0 (0) 0.38 14
a Mean G-to-A exchanges were detected in the indicated number of sequenced clon
sequenced amplicons is noted in parenthesis.
b Mean base changes detected in 474 non-guanine positions.In the course of our studies, we found that aberrant RNA
splicing of vif transcripts contributed to the truncation of Vif
fusion protein products. Aberrant vif splicing is conceivably a
consequence of removing vif gene expression from the context
of the viral genome and rev dependency. This became
apparent when comparing the splicing pattern of vif transcripts
during wild-type FIV infection and in cells where Vif was
expressed independently of the FIV genome (Supplementary
Fig. 1). When expressed alone, about one-half of the detected
vif transcripts utilized splice donor and acceptor sites contained
within the vif open reading frame. This splicing event is
predicted to truncate the vif open reading frame and create a
premature stop codon leading to the expression of an 11 amino
acid peptide. During FIV infection of CrFK cells, the majority
of the subgenomic vif transcripts comprise the full-length open
reading frame. Although internally spliced vif transcripts were
detected during FIV infection, the low intensity of these bands
suggests that these represent a minor fraction of the vif-
containing RNAs.
Our data that FIV-Oma Vif expression is confined to the
cytoplasm correlate with reports in HIV-1 (Goncalves et al.,
1994, 1995; Simon et al., 1997) and MVV (Audoly et al.,
1992) infected cells. Expression in the cytoplasm would be
consistent with a role of the Vif protein in regulating FIV
virus maturation or modifying the infectivity of the virus after
entry into a host cell by preventing APOBEC3G incorpora-
tion into virions. The cytoplasmic localization of HA-tagged
Vif in cells infected with FIV-Oma contradicts a previous
report showing FIV Vif expression in the nucleus. In this
report, Chatterji et al. (2000) demonstrated that the sub-
cellular localization of Vif in a feline astrocyte cell line,
G355, infected with the FIV 34TF10 strain, differed
depending upon the cellular fixation method prior to
immunostaining; Vif localization appeared cytoplasmic in
cells fixed with methanol and nuclear in cells fixed with 2%
formaldehyde. Our results indicate that FIV-Oma Vif expres-
sion is invariably cytoplasmic in CrFK cells using either
methanol or paraformaldehyde fixation. Thus, FIV Vif
subcellular localization may vary between domestic and
non-domestic cat strains of FIV or may differ depending upon
the cell type in which it is expressed.
A surprising finding in our study is that Vif expression in
trans was unable to rescue the replication of vif mutant viruses.
This result differs from published studies demonstrating that
HIV-1 Vif expression can abrogate the replication block for vif-ction of control CrFK cells and two clones of CrFK cells expressing Vif-RS
Day 10
quenced
lones
Mean G-to-A changesa
(range)
Mean other base
changesb
Sequenced
Clones
2.61 (0–6) 0.16 12
0.50 (0–2) 0.21 10
0.38 (0–2) 0.23 13
es from a possible 118 Gs within the analyzed region. The range of values from
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BEC3G incorporation into virions (Harris and Liddament,
2004). As members of the APOBEC3 family appear conserved
throughout vertebrate evolution, Vif proteins of lentiviruses
from primates (Harris and Liddament, 2004) and sheep
(Kristbjornsdottir et al., 2004) have co-evolved to counteract
the host anti-viral mechanism. Recent studies by Poss et al.
(2006) and Lochelt et al. (2005) indicate that the APOBEC3-
mediated mechanism of retroviral inhibition is conserved in
felines. In support of this, the feline foamy virus Bet protein has
been demonstrated to bind a feline APOBEC3 orthologue (fe3)
and inhibit the cytidine deamination of the spumavirus genome
(Lochelt et al., 2005). Our finding that fewer G-to-A mutations
in wild-type FIV-Oma replicating in CrFK cells stably over-
expressing FIV-Oma Vif suggests that FIV Vif is capable of
preventing APOBEC-induced mutations in cells from domestic
cats. However, the inability of Vif expression in trans to restore
infectivity of vif mutant viruses suggests that additional
functions of FIV Vif are not complimented in our system. It is
possible that the spatial or temporal expression of Vif in our
studies may not adequately reflect the native behavior of a
multifunctional protein. Analysis of the interaction of FIV Vif
and the feline APOBEC3 orthologue (fe3) will facilitate a
further understanding of the function of FIV Vif in viral
replication.
Materials and methods
Cell lines and virus
The FIV-Oma strain isolated from Pallas' cat used in this
study has been previously described (Barr et al., 1995,
1997). pOma3 is an infectious molecular clone derived from
the FIV-Oma isolate. The sequence of the pOma3 proviral
clone has been deposited in GenBank, accession number
AY713445.
CrFK cells (ATCC CCL-94) were grown in 70% MEM-H,
30% L-15 and 10% FBS supplemented with 25 mM HEPES
and 50 μg/mL gentamicin. MDCK cells (ATCC CCL-34) were
grown in MEM medium containing10% FBS and 50 μg/mL
gentamicin. Both cell lines were grown in 37 °C incubators with
5% CO2. All transfections were done using Lipofectamine
according to the manufacturer's protocols (Invitrogen). Clonal
cell lines derived from CrFK cells transfected with the HA-Vif-
RS vector were selected with 100 μg/mL zeocin in the same
medium. The DNA sequence of the vif open reading frame was
verified in both clonal cell lines expressing HA-Vif-RS.
Vif cloning, subcloning and expression
The FIV-Oma vif open reading frame was amplified from
pOma3 employing a forward primer 5′-AGATCTAT-
GAGTGGTGAAGAG-3′and a reverse primer 5′-GTCGACT-
TAACTCTTCATCCGA-3′ with Pfu polymerase (Stratagene)
(94 °C for 30 s, 50 °C for 30 s, 72 °C for 45 s) for 25 cycles. The
product was confirmed by DNA sequencing and cloned into the
pCR2.1 Topo TA cloning vector generating pvif/TA1. Theresultant plasmid was then cut with EcoRV/SalI to isolate the
vif fragment, which was subsequently cloned into pCDNA4/
HisMaxC digested with EcoRV/XhoI for mammalian expres-
sion studies.
Fusion proteins of Vif and EGFP were created by digesting
pvif/TA1 with PstI and BamHI and cloning the vif fragment
into the pEGFP-C3 vector (Clontech) digested with PstI and
BamHI to create an N-terminal EGFP-Vif fusion. A BglII/SalI
fragment from pvif/TA1, which deletes the 5′ portion of vif
through the predicted splice donor site, was cloned into EGFP-
C1 generating the vector EGFP-Vif sd-. Transient transfections
with these plasmids were done for 48 h, and then cells were
collected and frozen at minus 70 °C.
To express Vif in bacteria, an EcoRV/SalI fragment from
pvif/TA1 was cloned into the bacterial expression vector
pET28c (Novagen) cut with Ecl136II/XhoI. Additionally, the
EGFP-Vif fusion was cloned as an NcoI/SalI fragment from
pEGFP-Vif into the multiple cloning site of pET28a
(Novagen) digested with NcoI and SalI. These pET28-vif
plasmids were transformed into BL21DE3pLysS cells that
were subsequently treated with IPTG for 2 h to induce Vif
protein expression.
Generation of vif mutant FIV strains
FIV pOma3 VifΔ molecular clone was constructed by
digesting pOma3 with StuI and self-ligating the two unique
enzyme sites within the vif open reading frame. FIV Vif-fs was
made by site-directed mutagenesis of pOma3 using primers
forward 5 ′ -GGGGGACCTAGATAAGAGCTATGC-
TATGCTCTATATAGG-3′ and reverse 5′-CCTATATAGAG-
CAT AGCATAGCTCTTATCTAGGTCCCCC-3′with the
QuikChange kit from Stratagene. The primers insert a TA
dinucleotide (sequence underlined) at 67 bp within the vif open
reading frame causing the mutation of a SapI enzyme site and
forming premature termination codons. Following the con-
struction of both mutant molecular clones, DNA sequencing
verified that no additional sequence changes were introduced
during the cloning process. Infectivity of the molecular clones
was measured by a reverse transcriptase assay, using procedures
previously described (Zou et al., 1997). Aliquots from three
independent transfections were measured for RT activity at each
time point.
vif resynthesis
FIV-Oma vif gene was resynthesized using the primers
shown in Table 1. Amplification in 100 μL was as follows:
primer vif 1 and vif 2 at 1 nM, Taq polymerase ten cycles of
94 °C for 30 s, 40 °C for 30 s and 72 °C for 30 s then five cycles
of 94 °C for 30 s and 72 °C for 30 s. PCR products were
electrophoresed in 2% Nusieve gels, and bands were gel-
purified and added to the second amplification using adjacent
primer sets (e.g. vif 1 and vif 3). After synthesis with primers vif
1–6, vif 5F-12 and vif 11F-19, products were cloned in to
pCR2.1Topo TA vector and multiple clones were sequenced.
Reassembly of resynthesized vif gene was accomplished by
120 T.A. Paul et al. / Virology 361 (2007) 112–122cloning vif 1–6 cut with BamHI and EcoRI into pBluescript SK
(−), followed by digestion of the resultant clone and vif 5F-12
with StyI and EcoRI and ligation. The vif 11F-19 clone and the
Bluescript clone of vif 1–12 were then digested with EcoNI and
XhoI and fragments were ligated. The resultant vif clone was
named vif-RS. All DNA sequencing was performed at the core
facility at Cornell University Bioresource Center (Ithaca, NY).
For mammalian expression, the vif-RS digested with BamHI
and XhoI was subcloned into pEGFP-C1 cut with BglII and
SalI, to create an N-terminal EGFP fusion, EGFP-Vif-RS. The
same fragment was cloned into pCDNA4hismaxC cut with
BamHI and XhoI. This plasmid was then digested with SnaBI
and BamHI and ligated with a fragment containing a 3XHA tag
derived from the plasmid (a generous gift from Dr. Jun-Lin
Guan, Cornell University) digested with similar enzymes. This
process exchanges the CMV promoter and Xpress epitope of
pCDNA4hismaxC with the CMV promoter and 3X HA tag of
pKH3-FAK to create the HA-Vif-RS expression construct.
Western blots and immunofluorescence
Cell lysates used for western blots were dissolved in Nupage
(Invitrogen) sample buffer, boiled and run on Nupage 4–12%
Bis–Tris gels in MOPS buffer and electroblotted to nitrocellu-
lose as described in the manufacturer's protocol. Membranes
were probed with antibodies to anti-HA (Upstate), anti-GFP
(Invitrogen) and anti-FIV p24 (Biodesign International) fol-
lowed by incubation with species-specific secondary antibodies
conjugated to alkaline phosphatase. Immunoreactive bands
were detected with BCIP/NBT staining (KPL).
For indirect immunofluorescence staining, CrFK or MDCK
cells expressing HA-Vif-RS were grown to approximately 50%
confluency on 12-mm-diameter coverslips pretreated with
10 mg of poly-L-lysine per milliliter to aid cell attachment
and spreading. For FIV Gag localization, CrFK cells were
infected with supernatant from pOma3 transfected cells. Cells
were fixed with either ice-cold 100% methanol for 10 min or
3% paraformaldehyde in PBS (pH 7.4) for 15 min. Parafor-
maldehyde fixed cells were quenched with 50 mM NH4Cl and
permeabilized with 0.1% Triton X-100. After being blocked in
10% goat serum, cells were treated with mouse anti-FIV p24
IgG or rabbit anti-HA for 30 min. As secondary antibodies, we
used Texas red (TR)-labeled goat anti-mouse immunoglobulin
G and fluorescein isothiocyanate (FITC)-labeled goat anti-
rabbit immunoglobulin G (Zymed). Coverslips were mounted
with Vecta-shield (Vector Laboratories) containing DAPI stain.
Cells were viewed and photographed on a Zeiss Axiophot or
confocal microscope.
RNase protection
pvif/TA9 (opposite orientation of the PCR-cloned vif insert
to pvif/TA1) was linearized with DraI in order to make an
antisense transcript containing 138 nt from the 3′ end of vif and
78 nt of vector sequence (216 nt total). In vitro transcription was
performed with T7 RNA polymerase, using Ambion's RPA III
kit. Total RNA from transfected and infected CrFK cells wasprepared with the Rneasy kit (Qiagen). 8×104 cpm of in vitro
transcripts was annealed overnight to10 μg of total RNA. A 10-
bp ladder (Invitrogen) was labeled by a kinase-exhange reaction
with γ-ATP. Samples were electrophoresed on Novex 7%
acrylamide TBE/urea gels and exposed to X-ray film.
Analysis of mutations in replicating FIV
CrFK cells were transfected with the FIV-Oma infectious
clone pOma3 using Lipofectamine reagent (Invitrogen). Five
days post-transfection, equal volumes of supernatant were used
to infect 1×106 control CrFK cells as well as two clonal CrFK
cell lines expressing HA-Vif-RS. Infection of each line was
verified using indirect immunofluorescence staining procedures
described above. At 7 and 10 days post-infection, viral pellets
were prepared as previously described (Kristbjornsdottir et al.,
2004). Virion incorporated DNA was isolated with a DNA
Blood Mini Kit (Qiagen). Aliquots of 100 ng of DNA were
utilized in PCR reactions with a high fidelity Taq polymerase
(Invitrogen) using forward primers 5′-TAAGCAATGGCCTC-
TATCAAAA-3′ and reverse primers 5′-TAAAGCAATGG
CCTCTATCAAAA-3′ and conditions as follows: 94 °C for
30 s, 50 °C for 1 min and a 68 °C extension for 1 min, for 35
cycles. The resultant PCR products encompassing positions
2585–3177 within the pol region of pOma3 were cloned into
the pCR2.1 TA cloning vector. Fifteen independent cloned
products were DNA sequenced using M13F and M13R primers
and analyzed for DNA mutations.
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